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ABSTRACT: Kabuki syndrome (KS) is a multiple con-
genital anomalies syndrome characterized by character-
istic facial features and varying degrees of mental re-
tardation, caused by mutations in KMT2D/MLL2 and
KDM6A/UTX genes. In this study, we performed a mu-
tational screening on 303 Kabuki patients by direct se-
quencing, MLPA, and quantitative PCR identifying 133
KMT2D, 62 never described before, and four KDM6A
mutations, three of them are novel. We found that a num-
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ber of KMT2D truncating mutations result in mRNA
degradation through the nonsense-mediated mRNA de-
cay, contributing to protein haploinsufficiency. Further-
more, we demonstrated that the reduction of KMT2D
protein level in patients’ lymphoblastoid and skin fibrob-
last cell lines carrying KMT2D-truncating mutations af-
fects the expression levels of knownKMT2D target genes.
Finally, we hypothesized that the KS patients may bene-
fit from a readthrough therapy to restore physiological
levels of KMT2D and KDM6A proteins. To assess this,
we performed a proof-of-principle study on 14 KMT2D
and two KDM6A nonsense mutations using specific com-
pounds that mediate translational readthrough and thereby
stimulate the re-expression of full-length functional pro-
teins. Our experimental data showed that both KMT2D
and KDM6A nonsense mutations displayed high levels of
readthrough in response to gentamicin treatment, paving
the way to further studies aimed at eventually treating
some Kabuki patients with readthrough inducers.
C© 2014 The Authors. ∗Human Mutation published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
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cals, Inc.∗
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Introduction
Histonemethylation is an epigenetic mechanism by which spatial
and temporal expressionofdistinct genes andpathways are regulated
at precise developmental stages.Different histone lysinemethylation
states (mono-, di-, or tri-methylation) are associated with gene
transcriptional activation or repression depending on the location
of the lysine residue.
In general, histone H3 lysine 4 (H3K4) di- and tri-methylation
are linked to active transcription, whereas H3K27 di- and tri-
methylation are associated with gene silencing [Santos-Rosa et al.,
2002]. Aberrations in the histone modifiers have been associated
with genetic diseases, such as Kleefstra syndrome, Sotos syndrome,
Weaver syndrome, and Schinzel–Giedion syndrome [Berdasco and
Esteller, 2013]. The discovery of histone methyltransferase (HMT)
KMT2D (MIM #602113; RefSeq NM 003482.3, also known as
MLL2, ALR/MLL4) and demethylase KDM6A (MIM #300128; Ref-
SeqNM 021140.2, alsoknownasUTX) genetic alterations inKabuki
syndrome (KS) patients expanded and highlighted the role of hi-
stone modifiers in causing congenital anomalies and intellectual
disability [Bogershausen and Wollnik, 2013]. KS (MIM #147920)
is an autosomal-dominant condition characterized by striking fa-
cial features, such as elongated palpebral fissures with eversion of
the lateral third of the lower eyelid, short columella with depressed
nasal tip, skeletal anomalies, dermatoglyphic abnormalities, mild-
to-moderate mental retardation, and postnatal growth deficiency
[Kuroki et al., 1981; Niikawa et al., 1981]. KS is commonly asso-
ciated with congenital heart defects, genitourinary anomalies, cleft
lip and/or palate, susceptibility to infections, gastrointestinal ab-
normalities, ophthalmologic defects, ptosis and strabismus, dental
anomalies, including widely spaced teeth and hypodontia, and ear
pits. Additionally, KS individuals might have a number of less fre-
quent findings comprising visceral abnormalities and premature
breast development in females.
In 2010, whole-exome sequencing successfully identified het-
erozygous mutations in the KMT2D gene as the major cause of
KS [Ng et al., 2010]. Since then, 55%–65% of KS cases have been
reported carrying a KMT2D mutation [Ng et al., 2010; Hannibal
et al., 2011; Li et al., 2011; Micale et al., 2011; Paulussen et al.,
2011; Banka et al., 2012, 2013; Makrythanasis et al., 2013; Miyake
et al., 2013a]. The majority of mutations identified were de novo,
although familial cases with autosomal-dominant inheritance have
occasionally been described [Hannibal et al., 2011; Kokitsu-Nakata
et al., 2012]. KMT2D gene maps to 12q13.12 and encodes a gigantic
protein (5,537 residues) that belongs to the mixed lineage leukemia
(MLL) family of HMTs. The MLL proteins are part of the SET
(Su[var]3–9, enhancer-of-zeste, Trithorax) family of proteins [Dil-
lon et al., 2005] that play important roles in the epigenetic control
of active chromatin states [Issaeva et al., 2007]. They act as tran-
scriptional coactivators and are involved in the expression control
of genes essential for embryogenesis and development such as the
HOX genes [Ansari and Mandal, 2010; Eissenberg and Shilatifard,
2010].
A subset of KS individuals was recently identified with either
pointmutations ormicrodeletions encompassing theX-linked gene,
KDM6A [Lederer et al., 2012; Miyake et al., 2013a; Miyake et al.,
2013b] that encodes a Histone H3 lysine-27 demethylase. KDM6A
plays a crucial role in general chromatin remodeling [Hong et al.,
2007; Lan et al., 2007] and interacts with KMT2D, in a conserved
SET-1-like complex that trimethylates H3K4 [Issaeva et al., 2007].
The inactivation of the zebrafish kdm6a orthologue by morpholino
is associated with severe and diverse structural defects and devel-
opmental abnormalities [Lindgren et al., 2013]; this inactivation
resulted in the misregulation of HOX genes leading to a poste-
rior developmental defect, whereas Kdm6a-deficient mice showed
severe defects in heart development and embryonic lethality [Lee
et al., 2012].
The majority of KMT2D and KDM6A nucleotide changes are
truncating mutations (nonsense, frameshift, or splice site) that pro-
duce premature termination codons (PTCs), which are potentially
deleterious. In the last few years, there have been several attempts to
develop mutation-specific pharmacological approaches to restore
sufficient levels of functional proteins. One approach that has been
gaining prominence is that of using pharmacological agents to pro-
mote nonsense suppression or readthrough of PTCs thus enabling
re-expression of full-length functional proteins [Nakamura et al.,
2005; Bellais et al., 2010]. Thepotential of aminoglycosides andnon-
aminoglycosides as therapeutic tools has been demonstrated in sev-
eral genetic disorders such as hemophilia, β-thalassemia, and spinal
muscular atrophy, but most extensively in Duchenne muscular dys-
trophy and cystic fibrosis [Lee and Dougherty, 2012]. Interestingly,
this treatment was successfully applied on an Ataxia-telangiectasia
patient with heterozygous nonsense mutation, thereby demonstrat-
ing therapeutic ability despite the presence of a nonsense mutation
in just one allele [Nakamura et al., 2011].
In this report, we have expanded the spectrum of mutations of
KMT2D and KDM6A genes by analyzing our cohort of 303 Kabuki
patients by direct sequencing, MLPA and quantitative PCR (qPCR).
Based on KMT2D biological role, we designed functional studies
that highlighted the haploinsufficiency of KMT2D as one of the
mechanisms underlying the pathogenesis of the disease. Moreover,
we evaluated the readthrough efficiency of 14 KMT2D and two
KDM6A nonsense mutations and showed that 11 KMT2D and one
KDM6A nonsense mutation responded to gentamicin treatment
suggesting that this strategy can be effective to restore functional




In this study, 303 KS patients were included following the inclu-
sions criteria reported inMicale et al. (2011). Patients were enrolled
after obtaining appropriate informed consent by the physicians in
charge and approval by the respective local ethics committees.
Cell Cultures, Nonsense-Mediated mRNA Decay Assay,
and E2 Treatment
Lymphoblastoid cell lines (LCLs) were established from fresh
peripheral blood leukocytes, infected by Epstein Barr Virus and
cultured in RPMI 1640 supplemented with 10% of fetal bovine
serum (FBS; Life Technologies, USA), L-glutamine, and 1% an-
tibiotics mixture (penicillin and streptomycin 10,000 UI/ml; Life
Technologies). Primary skin fibroblasts were grown inminimumes-
sential medium supplemented with 1% L-glutamine, 10% FBS, and
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antibiotics. Nonsense-mediated mRNA decay (NMD) was assayed
by treating fibroblast and lymphoblast cell lines with puromycin at a
concentration of 200μg/ml. After 8 hr of incubation, total RNAwas
obtained using the RNasy mini Kit (Qiagen, Germany) according
to manufacturer instructions and Quantitect Reverse Transcrip-
tion kit (Qiagen, Du¨sseldorf, Germany) was used for cDNA synthe-
sis. Fibroblast cell lines were treated with 200 nM of 17B-estradiol
(E2), incubated for 8 hr and then harvested for RNA and protein
extraction.
MLPA, Long PCR, and Genomic Real-Time qPCR
Genomic DNAs were extracted from fresh and/or frozen periph-
eral blood leukocytes of the probands and their parents following
standard procedures. MLPA analysis was performed as reported in
Priolo et al. (2012)usingprobemixture (SALSAMLPAKITP389-A1
KMT2D; MRC-Holland, Amsterdam, The Netherlands) that con-
tains 27 probes targeting exons across the KMT2D gene.
Long PCR was carried out with Expand Long Template PCR
system (Roche,Mannheim, Germany) with combinations of primer
pairs spanning the KMT2D exons not covered by MLPA. qPCR
reactions were carried out with primers designed to amplify all the
29 KDM6A exons as described in Priolo et al. (2012).
Real-Time qPCR Assays
Total RNA was extracted from peripheral blood leukocytes using
TRIZOL reagent (Life Technology) and reverse transcribed using
the Quantitect Transcription kit (Qiagen), according to the man-
ufacturer’s instructions. Oligos for qPCR were designed using the
Primer express program [Rozen and Skaletsky, 2000] with default
parameters. EEF1A1 and GAPDH were used as references genes.
qPCR reactions and calculations were made as reported in Ferrero
et al. (2010). Significance was determined by a two-tailed unpaired
t-test for means.
Dual Luciferase Reporter Vector System
A dual gene reporter pCRFL (gently provided by Prof. J-P Rous-
set) was used to quantify the effect of gentamicin on stop mutation
readthrough in culture cells. Sequence to be analyzed spanning 27
nucleotides centered on the different stop mutations were inserted
in-framebetween theRenilla andFireflyLuciferase coding sequences
through site-directed mutagenesis by using the QuickChange II kit
(Stratagene, La Jolla, California, USA). All target DNA sequences
were assessed by sequencing. Plasmids were purified using Qia-
gen Midiprep Kit according to the manufacturer’s specifications.
HEK293 cells were culture in Dulbecco’s modified Eagle’s medium
supplementedwith 10%FBS, 1%antibioticsmixture, and incubated
at 37% in humidity saturated 5% CO2. Cells were transfected using
FuGeneHDTransfectionReagent (Promega)with each pCRFL con-
struct. Culture medium was replaced 24 hr later with fresh medium
at a concentration of gentamicin (Hospira, Lake Forest, Illinois,
USA) varying from 0 to 1,200 μg/ml. After 48 hr, the cells were
lysed in passive lysis buffer and assayed for both Firefly and Renilla
luciferase activity using the Dual-GLO R© Luciferase Assay System
(Promega, Madison, WI, USA).
This dual reporter allows the quantification of stop-codon
readthrough, by measuring Firefly and Renilla activities, as pre-
viously described [Bidou et al., 2004].
Briefly, readthrough efficiency was estimated by comparing the
Firelfly/Renilla luciferase ratio obtained for each nonsensemutation
to an in-frame control. A 100% activity control was provided by a
construct (TQ) with no stop codon between the coding sequences
of the two reporters [Sermet-Gaudelus et al., 2007]. A pCRFL re-
porter vector harboring the 319d Duchenne muscular dystrophy
mutation (pCRFL319), exhibiting the highest gentamicin-induced
readthrough efficiency and the highest induction factor inNIH3T3-
cultured cells assays [Bidou et al., 2004], was used as positive control.
Values are the mean ± SEM of three experimental replicates from
three independent transfections. Significance was determined by a
two-tailed unpaired t-test for means.
PCR-Based Sequencing of KMT2D and KDM6A
Mutation screening of all 54 coding exons of the KMT2D
gene was performed as reported in Micale et al. (2011). KDM6A
(NM 021140.2) primers were designed to amplify exons and ad-
jacent splice sites according to the reference sequences, using the
Primer 3 Output program (http://frodo.wi.mit.edu/primer3/). A
complete list of primer sequences and PCR conditions are avail-
able on request. The amplified products were subsequently puri-
fied and sequenced with a ready reaction kit (BigDye Terminator
v1.1 Cycle; Warrington WA1 4SR, UK). The fragments obtained
were purified using DyeEx plates (Qiagen) and resolved on an au-
tomated sequencer (3130xl Genetyc analyzer DNA Analyzer; ABI
Prism). Sequences were analyzed using the Sequencer software
(Gene Codes, Ann Arbor, MI). We resequenced all identified muta-
tions in independent experiments. The following databases were
used to obtain gene information: National Center for Biotech-
nology Information (NCBI, http://www.ncbi.nlm.nih.gov/), En-
sembl Genome Server (http://www.ensembl.org/), UCSC Genome
Bioinformatics (http://www.genome.ucsc.edu/), and 1000 genomes
(http://browser.1000genomes.org/). All existing and newmutations
were described following the recommendations of the Human
Genome Variation Society (http://www.hgvs.org/mutnomen).
In Silico Analysis
We analyzed the missense variants by the latest version of the
server Polyphen-2 version 2.2.2 (http://genetics.bwh.harvard.edu/
pph) (Adzhubei et al., 2010), Align GVGD (http://agvgd.iarc.fr/
agvgd_input.php) [Tavtigian et al., 2006], PROVEAN v1.1
(http://provean.jcvi.org/index.php) [Choi et al., 2012], and SIFT
v1.03 (http://sift.jcvi.org/) [Kumar et al., 2009], UMD-predictor
(http://www.umd.be/) [Frederic et al., 2009], using default parame-
ters. Splice-site variants were evaluated for putative alteration of reg-
ulatory process at the transcriptional or splicing levelwithNetGene2
(http://www.cbs.dtu.dk/services/NetGene2) [Brunak et al., 1991]
and NNSPLICE (http://www.fruitfly.org/seq_tools/splice.html)
[Reese et al., 1997].
Protein Extraction and Western Blot Analysis
Normal and patient lymphoblastoid and fibroblast cell lines
were treated with concentration of gentamicin varying from 800
to 1,200 μg/ml. After 48 hr, cells were lysed in 10-mM HEPES,
1.5-mMMgCl2, 10-mMKCl, 0.5-mMDTT, 1.5-mMPhenylmethyl-
sulfonyl fluoride (PMSF), and 2 N KCl. Proteins were separated
on a SDS-polyacrylamide gel. Western blots were prepared as re-
ported in Caratozzolo et al. (2012) and probed with anti-KMT2D
(Abnova, Taipei, Taiwan). Bound primary antibodies were visu-
alized using ECL western blotting or ECL plus Western blotting
detection reagents (GE Healthcare, UK).
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Results
Mutation Screening of KMT2D and KDM6A
Since 2011, we performed a comprehensive mutational screening
on 303 Kabuki patients by direct sequencing, MLPA, and qPCR on
KMT2D and KDM6A genes, respectively. Of these 303 patients, 79
were described in previous studies where 53 pathogenic KMT2D
mutations were identified in 51 patients (Supp. Table S1) [Micale
et al., 2011; Makrythanasis et al., 2013; Ratbi et al., 2013].
Here, we extended the KMT2D mutational analysis to a new
cohort of 224 individuals clinically diagnosed as KS identifying 82
(82/224, 36%) patients carrying causative KMT2D mutations.
Overall, in our whole KS cohort, we identified 133/303 (34%) pa-
tientswithKMT2Dmutations and 140 differentKMT2Dmutations;
of them, 87/140 (62%) were identified in this study with 66/140
(47%) never described before. The following types of KMT2D mu-
tations were identified: 37 nonsense (37/140, 26%), 42 frameshift
(42/140, 30%), 46 missense (46/140, 33%), eight splice site (8/140,
6%), and seven indel (7/140, 5%) (Supp. Tables S1 and S2). Almost
all identified mutations occurred de novo; only 16 missense and
four indel variants were inherited from an apparently asymptomatic
parent.
To explore the occurrence of intragenic deletions and duplica-
tions, we screened KMT2D exons by MLPA analysis on 207 KS
patients: 164 KMT2D point mutation negative, 37 with KMT2D
missense, and six indels. We identified the KB43 patient carry-
ing a singleton deletion covering from exon 49 to a part of exon
51 (Supp. Fig. S1A). Long PCR, followed by direct sequencing,
allowed us to map the boundaries of the deletion as c.15785-
238 16168del2425insTTGTATCTCAA mutation (Supp. Fig. S1B).
KMT2D mutations were submitted to the Leiden Open Varia-
tion Database (LOVD v.3.0; http://www.lovd.nl/3.0/home) public
database.
To identify KDM6A mutations in KS patients, we first as-
sessed KDM6A exon dosage by qPCR analysis on 139 sam-
ples with no KMT2D alteration without identifying any intra-
genic deletions and duplications. Then, we sequenced 29 cod-
ing exons of KDM6A along with its exon–intron boundaries
in 98 patients (not enough DNA was available for the re-
maining 41 samples). We identified four KDM6A point mu-
tations: one nonsense c.514C>T (p.Arg172X) [Banka et al.,
2014], one frameshift c.1846 1849delACTC (p.Thr616TyrfsX8),
one missense c.2939A>T (p.Asp980Val), and one splicing mu-
tation c.3284+3 3284+6delAAGT (p.Asn1070 Lys1094del). Two
of them occurred de novo; parental DNAs were unavailable
for the others. KDM6A mutations were submitted to LOVD
(http://www.lovd.nl/3.0/home) public database.
Characterization of KMT2D Splice-Site Mutations
We identified eight patients with KMT2Dmutations in the prox-
imity of the splice sites and we analyzed them by NetGene2 and
Fruitfly softwares to predict the molecular consequences of the ob-
served nucleotide changes. The availability of the RNA from those
KS patients, but one, allowed us to experimentally determine the
effect at the transcriptional or splicing level (Supp. Fig. S2). All
identified intronic KMT2D variants cause aberrant splicing of the
corresponding transcripts that result in a frameshift with the gen-
eration of a premature stop codon as reported below:
 c.177-2A>C (p.Ser59ArgfsX86) affects the essential nucleotide –2
of the splice acceptor site of intron 2. Real-time PCR analysis and
fragment sequencing of the carrier patient revealed skipping of
the entire exon 3 (Supp. Fig. S2A).
 c.400+1G>A (p.Ser59ArgfsX86) occurring within the GT splice
donor site in intron 3 resulted in the disruption of the canonical
splice site and again in skipping of exon 3 (Supp. Fig. S2B).
 c.400-3A>G (p.Gly134GlufsX74) creates a novel AG splice accep-
tor site in intron 3. Sequencing of the normal-sized fragment
amplified from patient’s cDNA revealed a transcript with an in-
sertion of an AG dinucleotide that corresponds to the effective
splice-site acceptor of intron 3 (Supp. Fig. S2C).
 c.13999+5G>A (p.Asn4614IlefsX5) occurs at nucleotide +5 of the
splice donor site of intron 42. Sequencing analysis of the real-time
PCR fragments confirmed that the observed shorter transcript
results from a splicing failure and exclusion of exon 42 in the
mRNA (Supp. Fig. S2D).
 c.14252-6_14252-5insGAAA (p.Val4751_GlufsX22) consists of a
four nucleotides insertion in intron 44 that causes skipping of
the entire exon 45 (Supp. Fig. S2E).
 c.14643+1G>A (p.Gln4882ProfsX36) occurring at nucleotide +1
of the splice donor site of intron 47 creates a novel splice acceptor
site within exon 48. The PCR products from patient’s cDNA
showed two bands, one of the expected size, and an additional
shorter band carrying a partial deletion of the exon 48 (Supp.
Fig. S2F).
 c.14644-3C>G (p.Glu4882ProfsX36) occurring at nucleotide –3
of the splice acceptor site of intron 47 determine the samemolec-
ular events caused by c.14643+1G>A mutation (Supp. Fig. S2G).
 c.4693+1G>A (p.Val1561ArgfsX11) mutation was previously
characterized and reported by Ratbi et al. (2013).
KMT2DMutant Transcripts Suffer NMD
KMT2D nonsense mutations may result in the partial transcripts
degradation through NMD pathway, contributing to protein hap-
loinsufficiency. To investigate this, we measured by qPCR the levels
ofKMT2DmRNA in three KS skin fibroblasts and four KS LCLs fol-
lowing treatmentwith puromycin, a known indirectNMD inhibitor
[Brichta et al., 2008]. After puromycin treatment, we observed a sig-
nificant 2.18-, 2.35-, and 4.01-fold increase in theKMT2D transcript
levels in KB186, KB153, and KB3 fibroblast cell lines, respectively
(Supp. Fig. S3A and Supp. Table S3E), and 1.93- and 1.69-fold for
KB48 and KB83 LCLs, compared with untreated cells, respectively
(Supp. Fig. S3C and Supp. Table S3F). The reduced amount of
KMT2D mRNA levels in mutated cell lines and its recovery follow-
ing puromycin treatment indicate that endogenousKMT2Dmutant
transcripts are subject to NMD. The physiological NMD substrate
SC-35 1.7 Kb was included as positive control (Supp. Fig. S3B–D)
[Brichta et al., 2008]. We confirmed these data by direct sequenc-
ing of real-time PCR on mRNA derived from fibroblasts of patients
KB186, KB153, KB3, showing that NMD inhibition restores the
expression of the KMT2D-mutated alleles (Supp. Fig. S3E–G).
KMT2DMutations Affect Its Activity in Patients Cell Lines
The large prevalence of KMT2D protein truncating mutations
suggests loss of function, and therefore the haploinsufficiency of
KMT2D as the likely mechanism for the KS phenotype. To assess
this, we measured the protein level of KMT2D in six KS LCLs, and
three KS fibroblast cell lines carrying truncating mutations, and
we found a significant reduction of KMT2D protein level when
compared with control cell lines (Fig. 1A–F and Supp. Table S3A).
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Figure 1. KMT2D methyltransferase activity is impaired in KS lymphoblastoid and fibroblast cell lines with KMT2D-truncating mutations.
(A–F): Immunoblotting analysis by using anti-KMT2D antibody on whole protein lysate from six (A and B) KS lymphoblastoid (KB41, KB44, KB45,
and KB82, KB83, KB153, and KB186) and three (C) fibroblast cell lines (KB186, KB153, and KB3) with nonsense mutations and frameshift mutations,
compared with control cell lines. Pool: pooled protein lysates from two control cell lines. D–F: The density of each band was determined by
densitometer. The expression level of KMT2D was determined by calculating the protein level for each sample, normalized to the corresponding
GAPDH level. G: qPCR was performed to measure the expression of known target genes of KMT2D (HOXC6, S100A2, S100A4, S100A5, S100A6) in
six KS–LCLs, compared with control cell lines. Scale bars represent standard errors. ∗P < 0.01.
To address whether truncated KMT2D mutations affect its tran-
scriptional activity, we measured the mRNA level of direct known
transcriptional target genes of KMT2D complex, includingHOXC6
[Ansari et al., 2011] and some members of the S100A family genes,
such as S100A2, S100A4, S100A5, and S100A6. As shown in Fig-
ure 1G, KMT2D targets were downregulated in KS LCLs cells (Supp.
Table S3B). Overall, these data show that the transcriptional activity
of KMT2D is impaired in KS patients.
HOXC6 Expression Is Affected in Kabuki Patients
Many of the KMT2D mutations mapped before the LXXLL do-
main required for KMT2D binding to estrogen receptors (ERs),
ERα, and ERβ. Previous studies demonstrated that KMT2D, in co-
ordination with ERα and ERβ, transcriptionally regulates HOXC6
in an Estradiol (E2)-dependent manner. We thus hypothesized that
the loss of the KMT2D–ER interaction affects ER gene expression.
qPCR showed that HOXC6 transcriptional level decreased in KS
fibroblast cells, a reduction that persists even after E2 treatment
(Fig. 2A and B and Supp. Table S3C). As KMT2D is associated with
HOXC6 via binding to the estrogen receptor element (ERE), located
in the HOXC6 promoter region, we assessed the ability of KMT2D
to bind to the HOXC6 EREs in three KS patients by a luciferase re-
porter assay.We transfected the pGL3–ERE1–ERE2 luciferase-based
reporter vector containing theHOXC6EREs sequences (schematized
in Fig. 2C) in KS and healthy fibroblast cell lines treated with E2
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Figure 2. Effect of KMT2D haploinsufficiency on E2-induced expression of HOXC6. A and B: HOXC6 transcriptional level was determined in three
KS patient fibroblast cell lines (KB153, KB186, and KB3) exposed to 100 nM E2 for 8 hr or not by using qPCR analysis, in comparison to a pool
of two normal fibroblast cell lines. C–E: HOXC6 promoter fragment spanning the ERE1–ERE2 regions was cloned into a luciferase-based reporter
construct (pGL3) and transfected into three KS patient fibroblast cell lines and into two normal fibroblast cell lines along with a Renilla luciferase
construct used as an internal transfection control. Cells were then treated with 100 nM E2 (E) for 8 hr and subjected to luciferase assay. The
luciferase activities (normalized to Renilla activity) in the presence or not of E2 over normal fibroblast cell lines were plotted. The experiment with
three replicates was repeated at least thrice. Scale bars represent standard errors. ∗P < 0.01.
for 8 hr, then we measured the luciferase activity. Using a two-tailed
unpaired t-test, we detected a significant reduction of the luciferase
activity in all patient fibroblast cell lines (Fig. 2D and E and Supp.
Table S3D), in both treated or not with E2, when compared with
control cells transfected with pGL3 alone. Overall, these data in-
dicate that KMT2D mutations impair the regulation of HOXC6 in
Kabuki cell lines.
KMT2D and KDM6A Nonsense Mutations Are Responsive to
Gentamicin-Induced Readthrough Treatment
A large number of KMT2D and KDM6A mutations are non-
sense mutations that produce aberrant PTCs that are potentially
deleterious. We evaluated the potential ability of gentamicin in sup-
pressing KMT2D and KDM6A nonsense mutations by using an in
vitro readthrough reporter system [Floquet et al., 2011]. Fourteen
KMT2D and two KDM6A nonsense mutations were selected and
tested. The mutations were selected, when possible, following the
hypothetical rule of a uracil immediately upstream and a cyto-
sine just downstream the stop codon as associated with an optimal
gentamicin-induced readthrough, respectively [Floquet et al., 2012].
For each mutation, sequences spanning 27 nucleotides centered on
the different stopmutationswere inserted into the dual reporter vec-
tor pCRFL in-frame between Renilla and Firefly luciferase coding
sequences [Floquet et al., 2011]. Readthrough levels were quanti-
fied in HEK293 cells transiently transfected by the dual reporter
vector in the presence of increasing amounts of gentamicin. Cy-
totoxicity experiments demonstrated that no signs of cytotoxicity
were detectable after 48 hr of treatment with up to 1,200 μg/ml
of gentamicin (data not shown). The difference between basal and
gentamicin-induced readthrough level was statistically significant
(P < 0.01) for 11 KMT2D and one KDM6A nonsense mutations
(Fig. 3A and B and Supp. Table S4), although with a wide variability
in strength. In agreement with the previous report [Floquet et al.,
2012], we found that 11/12 (92%) of the mutations responsive to
gentamicin have a uracil in –1 residue immediately upstream the
stop codon and/or a cytosine in +4 position confirming that the
presence of these residues promotes higher basal and gentamicin-
induced readthrough than other nucleotides. To test the in vivo
effectiveness of gentamicin, we evaluated the expression levels of
two known targets of KMT2D, HOXC6, and S100A4 in LCLs from
KS patients cultured in the presence of gentamicin. qPCR analysis
revealed that KB41 LCL resulted in sixfold and threefold increase of
HOXC6 and S100A4 mRNA levels, respectively (Fig. 3C). In agree-
ment with the in vitro assay, a significant increase of S100A4mRNA
levels was observed in KB45 cells, whereas we did not detect any
significant increase of HOXC6 expression (Fig. 3D). These findings
are consistent with our in vitro observations about the effectiveness
of readthrough that varies with respect to type of mutations and
patient cell lines.
Overall, these studies suggest that readthrough strategies can
be effective to restore functional KMT2D and KDM6A activity,
although testing additional mutations, many other compounds and
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Figure 3. Identification of KMT2D and KDM6A nonsense mutations responsive to gentamicin treatment. A and B: Comparison between basal
and gentamicin-induced readthrough level. Readthrough efficiency for 14 nonsense mutations in the KMT2D gene and for two elsewhere published
[Miyake et al., 2013b] nonsense mutations in the KDM6A gene was assessed in HEK293 cells exposed or not to 600–800–1,200 μg/ml of gentamicin
for 48 hr. A pCRFL reporter vector harboring the 319d Duchenne muscular dystrophy mutation was used as positive control (CNT). Each value
corresponds to themean of four to six independent experiments. Scale bars represent standard errors. C andD: Gentamicin restored the expression
of HOXC6 and S100A4 in patient cultured cells with different efficiency. qPCR analysis was performed to evaluated HOXC6 and S100A4 expression
level in two patients LCLs, KB41 (C) and KB45 (D), and two control cell lines treated or not with 800 μg/ml of gentamicin for 48 hr. The results are
the mean from at least two experiments performed in duplicate. ∗P < 0.01.
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different cell lines aremandatory to assess their potential therapeutic
effectiveness.
Discussion
The orchestrated organization of epigenetic factors that control
chromatin dynamism, including chromatin-remodeling proteins, is
essential for the proper function of tissue homeostasis, cell identity,
and development [Berdasco and Esteller, 2013]. KS is the most
common of a growing group of multiple malformation syndromes
associated to developmental delay that are caused by mutations in
genes that encode proteins involved in histone methylation. In this
study, we identified 133 KMT2D and four KDM6A mutations in
303 patients clinically diagnosed with KS. The mutation detection
rates for KMT2D and KDM6A in KS suggest that other causative
genes may be involved, although it can be taken into account that a
number of these patients might have been misdiagnosed.
We demonstrated that KMT2D protein level is reduced and its
activity impaired in KS cell lines. KMT2D through H3K4 methy-
lation activity is a key epigenetic transcriptional regulator of the
expression of multiple genes with related functions, including em-
bryogenesis, development, and stem cell differentiation. Addition-
ally, KMT2D-associated histone methyl transferase activity appears
to be functional only in the context of its multiprotein complex,
including ASH2L, RBBP5, WDR5, and other MLL family members
[Issaeva et al., 2007; Dhar et al., 2012] and each KMT2D-interacting
protein plays a distinct role in regulating MLL-mediated histone
methylation and gene activation. In agreement with its biological
function, the lack of KMT2D protein activity or of its ability to form
a multiprotein complex might alter its role in histone methylation
pathway with strong influences on global change in gene expression
in many of the body’s organs and tissues, resulting in some of the
abnormalities of postnatal development of KS.
Inour screening,we found46missense variants distributed across
the entire length of theKMT2D gene including residues in PHD and
SET domain. The in silico analysis predicts thatmany of themmight
be pathogenic, although the exact role they play in the disease has
not been addressed. Recently, it has been shown that KSC1430R and
C1471Y missense mutations [Hannibal et al., 2011] in PHD4–6 do-
mains reduce PHD4–6 binding ability and abrogate the nucleosomal
methylation activity of KMT2D, although they do not affect the in-
teraction of KMT2D with ASH2L, RBBP5, and WDR5 [Dhar et al.,
2012]. These results offer a valuable and feasible assay to test the
pathogenicity of KMT2D missense mutations and implicate that
the missense mutations described here that lies in PHD domains
may contribute to KS by reducing KMT2D enzymatic activity and
consequently its mediated transcriptional activation.
The majority of genetic alterations detected in Kabuki patients
result in truncated proteins upstream the LXXLL domain, which is
involved in KMT2D-complex binding to ERα. Rationally, the loss
of the KMT2D–ERα interacting region might result in a dramatic
alteration of the ERα-mediated pathways. Notably, some of the
clinical features associated to deregulated ERα-signaling pathways
are included in the large spectrum of KS phenotypes, comprising
immunological defects and cardiac anomalies [Deroo and Korach,
2006]. Moreover, more than 20% of Kabuki patients show early
breast development consistent with the biological role of ERα in
mammary gland formation. In this regard, it was recently reported
that the homeobox (HOX)-containing geneHOXC6, a critical player
in mammary gland development andmilk production, is transcrip-
tionally activated via coordination of KMT2D and ER in an estro-
gen environment in breast cancer and placental choriocarcinoma
cells. Specifically, the HMTs, KMT2D, and MLL3, in coordination
with ERs, ERα, and ERβ, play critical roles in histone H3 lysine-4
trimethylation and in the recruitment of general transcription fac-
tors and RNA polymerase II in the EREs regions of the HOXC6
promoter during E2-dependent transactivation, leading to HOXC6
transcriptional activation. Interestingly, the knockdown of KMT2D
by using specific antisense oligonucleotides suppressed E2-induced
expression of HOXC6 [Ansari et al., 2011]. In agreement with all
these findings, we found that HOXC6 expression is impaired in KS
patients’ cell lines.
As Kabuki patients’ cell lines with KDM6A mutations were not
available, it was not possible to study the activity of the endogenous
KDM6A. However, it has been recently evaluated that the haploin-
sufficiency of Kdm6a in a zebrafish model. Kdm6a knockdown fish
exhibited abnormal craniofacial structures that included the ab-
sence of the branchial arches and otoliths, as well as the absence,
clefting, or inversion of the ceratohyal and abnormal patterning or
clefting of Meckel’s cartilages [Lindgren et al., 2013]. In addition,
Kdm6a-deficient mice showed severe defects in heart development
and embryonic lethality [Lee et al., 2012]. Very recently, it was
demonstrated that Kdm6a knockdown affects expression of master
regulatory genes involved in adipogenesis and osteogenesis [Hem-
ming et al., 2014]. These observations further support the hypoth-
esis that perturbation of a regulatory pathway shared by KDM6A is
responsible for the clinical aspects of the KS.
The large size of the KMT2D cDNA hampers so far the devel-
opment of any gene-therapy-based strategy. Mutation-based treat-
ments are something of recent enough in geneticmedicine, in which
the nature of themutation dictates the therapeutic strategy. As proof
of principle, here we demonstrated the ability of gentamicin to in-
duce the readthrough of naturally occurring stop mutations in the
KMT2D and KDM6A genes using both in vitro and in vivo as-
says. Readthrough efficiency has been shown to also depend on
the nature of the sequences surrounding the stop codon. Specif-
ically, the consensus sequence U-STOP-C results in an optimal
gentamicin-induced readthrough [Floquet et al., 2012]. However,
the readthrough response to treatment is highly variable and little
is known about the rules governing it and the response to differ-
ent compounds. A wide variability in responsiveness to gentamicin
was observed in our group of KMT2D and KDM6A mutations.
Interestingly, the c.12844C>T mutation that exhibited the highest
gentamicin-induced readthrough efficiency, follows the theoretical
rule in that a timine residue is located immediately upstream and a
cystein downstream from the stop codon.
After confirming in vitro nonsense suppression in KS, our study
goes one step further to investigate the in vivo effectiveness of gen-
tamicin on two cultured patient LCLs carrying nonsensemutations.
Consistent with our in vitro data, we showed that gentamicin treat-
ment is able to partially restore a functional endogenous KMT2D
protein confirming the use of the in vitro assay as a good model for
evaluating drug-induced readthrough and selecting patient carrying
nonsense mutations that could benefit from treatment. Neverthe-
less, studies on a larger number of KS cell lines are mandatory.
Our analysis indicated that some of KMT2D-truncating tran-
scripts suffer NMD process contributing to instability of mutant
mRNA and haploinsufficiency of KMT2D protein, thus it is pos-
sible that NMD minimizes the effect of readthrough treatment for
some KMT2D transcripts. To overcome this undesirable contingent
issue, the readthrough strategy might be combined with inhibition
of NMD by specific inhibitors and/or siRNA directed against NMD
key factors as UPF1 or UPF2.
Several other aminoglycosides and nonaminoglycosides agents
are used for their nonsense suppression activity in various types of
848 HUMANMUTATION, Vol. 35, No. 7, 841–850, 2014
cell culture with a different efficiency. Our preliminary results en-
courage further testing with other compounds including additional
aminoglycoside such as G418 and amikacin, and nonaminoglyco-
sides agents with improved biocompatibility, such as PTC124 and
RTC13, RTC14, and NB30 [Bordeira-Carrico et al., 2012].
Conclusions
This study expanded the picture of KMT2D and KDM6A muta-
tions that cause KS, adds some insight in the functionalmechanisms
that cause the disease, and finally provides the first preliminary
proof-of-concept that naturally occurring nonsense mutations in
KMT2D and KDM6A can be effectively suppressed providing a ra-
tional strategy for identifyingpatients likely to respondand therefore
more likely to benefit from treatment with readthrough inducers.
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